The latest public information from the National Medical Products Administration shows that a domestic silicone resin facial filler has passed the approval of Class III medical devices. The product adopts a hyperbranched structure design, with a thixotropic index of 4.7, and the morphological retention time after injection is extended to 1.8 times that of traditional materials. Clinical data show that the incidence of inflammatory reactions is 60% lower than that of imported products. Industry insiders revealed that the material has broken through the technical difficulties of surface hydroxyl modification and achieved dynamic mechanical matching with human tissue. With the popularization of the concept of "light medical beauty", it is estimated that the market size of medical silicone resin will exceed 3 billion yuan in 2024, with an annual compound growth rate of 28%.
Products-IOTA